Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In 2023, the company finalized ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc.

NodThera, a privately-held biotech working in chronic inflammatory diseases through selective modulation of the NLRP3 ...

J&J’s Innovative Medicine business continued its solid growth in the second quarter of 2025 with sales rising 4.9% year over ...

Investing.com - BMO Capital has lowered its price target on Amgen (NASDAQ: AMGN) to $335.00 from $346.00 while maintaining an Outperform rating. The prominent biotechnology company, which has ...

BMO Capital noted strong year-over-year prescription trends for several Amgen products, including Evenity (+28%), Repatha (+35%), and Tezspire (+64%), with their updated estimates for these products ...

The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 ...